Sunway Biotech is awarded the 14th in the biotechnology service industry in the 2021 TOP 5000 large-scale enterprise ranking!
- Author: sunway
- Category: Company News
Related posts
Interview from PharmaBoardRoom: George J. Lee, Ph.D. – Chairman; Tzu-Ming Pan, Ph.D – Vice Chairman and Chief Technology and Science Officer, SunWay Biotech, Taiwan
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the same compounds.
- Author: sunway
- Category: Company News
[Announcement] With an anti-counterfeiting label, it is recognized as a genuine product from SunWay Biotech!
It has come to our attention that some unscrupulous manufacturers and sellers have attempted to profit from the reputation and quality of SunWay’s brand by pedaling inferior counterfeit knock-offs. To ensure that you receive only genuine SunWay products, please ensure that there is an anti-counterfeiting label on your product since the beginning of this year. The anti-counterfeiting label is disposable and cannot be used again once it is torn. Consumer safety is SunWay’s highest concern, and we ask for your vigilance and assistance in identifying any counterfeit products. If you have any questions, please feel free to contact SunWay customer support. Customer Service: +886-2-2792-9568
- Author: sunway
- Category: Company News
ANKASCIN® 568-R red yeast rice extract shows benefits to manage total cholesterol and LDL-C
The first clinical study, which has been published in the Journal of Food and Drug Analysis, documents that ANKASCIN® 568-R is effective in reducing subjects’ serum cholesterol and low-density lipoprotein cholesterol (LDL-C) to nearly desirable levels in as little as 4 weeks and were maintained in 8 weeks. Forty subjects (Inclusion criteria: LDL-C in the range of 130-190 mg/dL and serum cholesterol greater than 180 mg/dL) completed the double-blind, placebo-controlled randomized 12-week study. The administration group took 110 mg ANKASCIN® 568-R/one capsule/day for eight weeks. After four weeks of treatment (110 mg ANKASCIN® 568-R/day), the changes in the lipid levels showed that the active products had a more favorable effect than the placebo. Compared to the baseline, statistically significant decreases of 11.9% and 19.0% were observed in TC and LDL-C levels, respectively (p < 0.05 for all pairs). This study demonstrated that subjects administered 110 mg of ANKASCIN® 568-R for more than four weeks exhibited a significant reduction in serum TC and LDL-C levels. To assess the safety of this ingredient, scientists assayed aspartate transaminase (AST) and alanine aminotransferase (ALT) levels in the liver, and blood urea nitrogen (BUN), creatinine, and uric acid levels in the kidney. The results imply no significant effect on renal metabolism and physiological function. These results indicate that supplementation of ANKASCIN® 568-R reduces the risks of serum TC and […]
- Author: sunway
- Category: Company News